Serum proprotein convertase subtilisin/kexin type 9 levels correlate with depression severity in post-stroke patients

BACKGROUND Post-stroke depression (PSD) is a common neuropsychiatric complication affecting an estimated 30%-40% of stroke survivors and adversely affecting rehabilitation and quality of life. Emerging evidence suggests that proprotein convertase subtilisin/kexin type 9 (PCSK9) may be involved in neuroinflammation and mood regulation. Evolocumab, a PCSK9 inhibitor, may have effects beyond lipid lowering when added to statin therapy; however, its association with depressive symptoms in patients with PSD remains unclear. AIM To investigate the association between serum PCSK9 levels and depression severity in patients with PSD receiving evolocumab plus statin therapy and to assess the association of this combination with changes in depressive symptoms. METHODS This retrospective study included 128 patients with PSD: 64 received evolocumab (140 mg every 2 weeks) plus atorvastatin (20 mg daily), and 64 received atorvastatin alone (20 mg daily). The primary outcomes were serum PCSK9 concentrations and 17-item Hamilton Depression Rating Scale (HAMD-17) scores at baseline and at weeks 4, 8, and 12. Secondary outcomes included Hamilton Anxiety Scale (HAMA) scores, lipid profiles, inflammatory markers [interleukin-6 (IL-6), tumor necrosis factor-α, and high-sensitivity C-reactive protein], and cognitive function assessed using the Montreal Cognitive Assessment (MoCA). Correlation analyses examined associations between PCSK9 concentrations and clinical outcomes. RESULTS At week 12, serum PCSK9 levels decreased from 385.6 ± 78.4 ng/mL to 156.3 ± 42.1 ng/mL in the combination-therapy group, compared with 378.2 ± 76.9 ng/mL to 298.5 ± 68.7 ng/mL in the atorvastatin-only group (P < 0.001). HAMD-17 scores decreased from 22.8 ± 4.5 to 10.2 ± 3.1 and from 22.3 ± 4.2 to 14.6 ± 3.8, respectively (P < 0.001 for the between-group comparison at week 12). Serum PCSK9 levels were positively correlated with HAMD-17 scores at week 12 (r = 0.652, P < 0.001). Compared with the atorvastatin-only group, the combination-therapy group had lower week-12 HAMA scores (8.5 ± 2.3 vs 12.1 ± 3.2, P < 0.001) and IL-6 concentrations (3.2 ± 0.8 pg/mL vs 5.1 ± 1.2 pg/mL, P < 0.001), higher MoCA scores (25.8 ± 2.1 vs 23.4 ± 2.6, P = 0.001), and a higher depression treatment response rate (73.4% vs 48.4%, P = 0.003). CONCLUSION In this retrospective, evolocumab added to atorvastatin was associated with greater reductions in serum PCSK9 levels and depressive symptom scores than atorvastatin alone. The correlation between PCSK9 concentrations and depression severity suggests that PCSK9 warrants further investigation as a potential biomarker in PSD. Prospective studies are needed to establish whether PCSK9 inhibition improves depressive symptoms.

Authors

Institutions

Publication Details

Journal
World Journal of Psychiatry
Published
2026-11-19
DOI
https://doi.org/10.5498/wjp.122026
Primary Topic
Stroke Rehabilitation and Recovery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serum proprotein convertase subtilisin/kexin type 9 levels correlate with depression severity in post-stroke patients

Xiaoyang Sun, Yue Yang, Meng-Jun Zhang, Shu-Gen Wang et al.
1 links
World Journal of Psychiatry
Stroke Rehabilitation and Recovery
article

Serum proprotein convertase subtilisin/kexin type 9 levels correlate with depression severity in post-stroke patients

Xiaoyang Sun, Yue Yang, Meng-Jun Zhang, Shu-Gen Wang, Hong-Yan Song
article en

Abstract

BACKGROUND Post-stroke depression (PSD) is a common neuropsychiatric complication affecting an estimated 30%-40% of stroke survivors and adversely affecting rehabilitation and quality of life. Emerging evidence suggests that proprotein convertase subtilisin/kexin type 9 (PCSK9) may be involved in neuroinflammation and mood regulation. Evolocumab, a PCSK9 inhibitor, may have effects beyond lipid lowering when added to statin therapy; however, its association with depressive symptoms in patients with PSD remains unclear. AIM To investigate the association between serum PCSK9 levels and depression severity in patients with PSD receiving evolocumab plus statin therapy and to assess the association of this combination with changes in depressive symptoms. METHODS This retrospective study included 128 patients with PSD: 64 received evolocumab (140 mg every 2 weeks) plus atorvastatin (20 mg daily), and 64 received atorvastatin alone (20 mg daily). The primary outcomes were serum PCSK9 concentrations and 17-item Hamilton Depression Rating Scale (HAMD-17) scores at baseline and at weeks 4, 8, and 12. Secondary outcomes included Hamilton Anxiety Scale (HAMA) scores, lipid profiles, inflammatory markers [interleukin-6 (IL-6), tumor necrosis factor-α, and high-sensitivity C-reactive protein], and cognitive function assessed using the Montreal Cognitive Assessment (MoCA). Correlation analyses examined associations between PCSK9 concentrations and clinical outcomes. RESULTS At week 12, serum PCSK9 levels decreased from 385.6 ± 78.4 ng/mL to 156.3 ± 42.1 ng/mL in the combination-therapy group, compared with 378.2 ± 76.9 ng/mL to 298.5 ± 68.7 ng/mL in the atorvastatin-only group (P < 0.001). HAMD-17 scores decreased from 22.8 ± 4.5 to 10.2 ± 3.1 and from 22.3 ± 4.2 to 14.6 ± 3.8, respectively (P < 0.001 for the between-group comparison at week 12). Serum PCSK9 levels were positively correlated with HAMD-17 scores at week 12 (r = 0.652, P < 0.001). Compared with the atorvastatin-only group, the combination-therapy group had lower week-12 HAMA scores (8.5 ± 2.3 vs 12.1 ± 3.2, P < 0.001) and IL-6 concentrations (3.2 ± 0.8 pg/mL vs 5.1 ± 1.2 pg/mL, P < 0.001), higher MoCA scores (25.8 ± 2.1 vs 23.4 ± 2.6, P = 0.001), and a higher depression treatment response rate (73.4% vs 48.4%, P = 0.003). CONCLUSION In this retrospective, evolocumab added to atorvastatin was associated with greater reductions in serum PCSK9 levels and depressive symptom scores than atorvastatin alone. The correlation between PCSK9 concentrations and depression severity suggests that PCSK9 warrants further investigation as a potential biomarker in PSD. Prospective studies are needed to establish whether PCSK9 inhibition improves depressive symptoms.

World Journal of PsychiatryVol. 16(11)
Cangzhou Central Hospital (CN)
Good health and well-being
Stroke Rehabilitation and Recovery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon